Biotech Funding, IPOs, and Trial Miss
Kilder
- GEN: Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines
- Firstwordpharma: Sensible gets $47M boost to scale manufacturing of next-gen mRNA medicines - FirstWord Pharma
- European-biotechnology: Sensible secures $47M to rethink mRNA manufacturing - European Biotechnology Magazine
- Endpoints: ArriVent's lung cancer drug firmonertinib fails key late-stage trial, stock tanks
- Kelofm: ArriVent’s cancer pill fails to ‘meaningfully’ delay disease progression, shares dive - 95.7 KELO-FM
- Uk: ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low - Yahoo Finance UK
- Seeking Alpha: ArriVent stock plunges on cancer trial failure (AVBP:NASDAQ) - Seeking Alpha
- BioPharma Dive: Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
- Endpoints: Lycia seeks IPO for antibody degraders as TRexBio, Retension set terms
- Endpoints: KymaThera, Rouge raise VC funding; Vaxcyte, Spyre do public offerings
- GEN: Biologics Standards for Innovation, Quality and Access
- Mtairynews: Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability - mtairynews.com
- wikimedia: Photo by NASA Johnson Space Center / Wikimedia Commons / Public domain
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.